
|Videos|September 12, 2021
Dr. Kaplan discusses patient selection for BPH treatments
Author(s)Urology Times staff
“This is the beginning of an exploration and an identification,” says Steven A. Kaplan, MD.
Advertisement
In this video, Steven A. Kaplan, MD, discusses his patient selection process for BPH treatments and shares the take-home message of the study, “UroLift PUL compared to Rezum, TURP and GreenLight PVP: US Medicare and commercial claims analysis reveals lowest complications for PUL and highest retreatment for Rezum,” presented at the 2021 American Urological Association annual meeting. Kaplan is a professor of urology at the Icahn School of Medicine and director of the Men’s Wellness Program at Mount Sinai, New York, New York.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves Titan Prime Inflatable Penile Prosthesis
2
FDA approves cefepime and zidebactam for complicated UTI
3
Phase 1 AcTION trial establishes RP2D for 225Ac-PSMA-617
4
Enzalutamide associated with greater cognitive decline than darolutamide in advanced prostate cancer
5











